Please use this identifier to cite or link to this item:
https://doi.org/10.1038/onc.2016.374
DC Field | Value | |
---|---|---|
dc.title | The hot-spot p53R172H mutant promotes formation of giant spermatogonia triggered by DNA damage | |
dc.contributor.author | Xue, Y | |
dc.contributor.author | Raharja, A | |
dc.contributor.author | Sim, W | |
dc.contributor.author | Wong, E.S.M | |
dc.contributor.author | Rahmat, S.A.B | |
dc.contributor.author | Lane, D.P | |
dc.date.accessioned | 2020-10-23T02:30:37Z | |
dc.date.available | 2020-10-23T02:30:37Z | |
dc.date.issued | 2017 | |
dc.identifier.citation | Xue, Y, Raharja, A, Sim, W, Wong, E.S.M, Rahmat, S.A.B, Lane, D.P (2017). The hot-spot p53R172H mutant promotes formation of giant spermatogonia triggered by DNA damage. Oncogene 36 (14) : 2002-2013. ScholarBank@NUS Repository. https://doi.org/10.1038/onc.2016.374 | |
dc.identifier.issn | 09509232 | |
dc.identifier.uri | https://scholarbank.nus.edu.sg/handle/10635/179209 | |
dc.description.abstract | Overexpression of mutant p53 is a common finding in most cancers but testicular tumours accumulate wild-type p53 (wtp53). In contrast to the accepted concept that p53 homozygous mutant mice do not accumulate mutant p53 in normal cells, our study on a mutant p53 mouse model of Li-Fraumeni syndrome harbouring the hot-spot p53R172H mutation described an elevated level of mutant p53 in non-cancerous mouse tissues. Here we use detailed immunohistochemical analysis to document the expression of p53R172H in mouse testis. In developing and adult testes, p53R172H was expressed in gonocytes, type A, Int, B spermatogonia as well as in pre-Sertoli cells and Leydig cells but was undetectable in spermatocytes and spermatids. A similar staining pattern was demonstrated for wtp53. However, the intensity of wtp53 staining was generally weaker than that of p53R172H, which indicates that the expression of p53R172H can be a surrogate marker of p53 gene transcription. Comparing the responses of wtp53 and p53R172H to irradiation, we found persistent DNA double-strand breaks in p53R172H testes and the formation of giant spermatogonia (GSG) following persistent DNA damage in p53R172H and p53-null mice. Strikingly, we found that p53R172H promotes spontaneous formation of GSG in non-stressed p53R172H ageing mice. Two types of GSG: Viable and Degenerative GSG were defined. We elucidate the factors involved in the formation of GSG: the loss of p53 function is a requirement for the formation of GSG whereas DNA damage acts as a promoting trigger. The formation of GSG does not translate to higher efficacy of testicular tumorigenesis arising from mutant p53 cells, which might be due to the presence of delayed-onset of p53-independent apoptosis. © 2017 The Author(s). | |
dc.publisher | Nature Publishing Group | |
dc.rights | Attribution 4.0 International | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.source | Unpaywall 20201031 | |
dc.subject | aurora B kinase | |
dc.subject | beta galactosidase | |
dc.subject | caspase 3 | |
dc.subject | cyclin A2 | |
dc.subject | cyclin D1 | |
dc.subject | cycline | |
dc.subject | histone gamma h2ax | |
dc.subject | histone H2AX | |
dc.subject | histone H3 | |
dc.subject | protein MDM2 | |
dc.subject | protein p21 | |
dc.subject | protein p53 | |
dc.subject | tumor suppressor p53 binding protein 1 | |
dc.subject | unclassified drug | |
dc.subject | arginine | |
dc.subject | histidine | |
dc.subject | mutant protein | |
dc.subject | adult | |
dc.subject | animal cell | |
dc.subject | animal experiment | |
dc.subject | animal model | |
dc.subject | animal tissue | |
dc.subject | apoptosis | |
dc.subject | Article | |
dc.subject | cell cycle progression | |
dc.subject | cell proliferation | |
dc.subject | controlled study | |
dc.subject | DNA damage | |
dc.subject | DNA damage response | |
dc.subject | double stranded DNA break | |
dc.subject | embryo | |
dc.subject | gene expression | |
dc.subject | gene sequence | |
dc.subject | genetic transcription | |
dc.subject | giant spermatogonia | |
dc.subject | hereditary tumor | |
dc.subject | immunohistochemistry | |
dc.subject | in situ hybridization | |
dc.subject | intron | |
dc.subject | irradiation | |
dc.subject | Leydig cell | |
dc.subject | male | |
dc.subject | mouse | |
dc.subject | newborn | |
dc.subject | nonhuman | |
dc.subject | primordial germ cell | |
dc.subject | priority journal | |
dc.subject | promoter region | |
dc.subject | protein depletion | |
dc.subject | protein function | |
dc.subject | seminiferous tubule epithelium | |
dc.subject | Sertoli cell | |
dc.subject | spermatid | |
dc.subject | spermatocyte | |
dc.subject | spermatogenesis | |
dc.subject | spermatogonium | |
dc.subject | staining | |
dc.subject | amino acid substitution | |
dc.subject | animal | |
dc.subject | DNA damage | |
dc.subject | genetics | |
dc.subject | mammalian embryo | |
dc.subject | metabolism | |
dc.subject | mutation rate | |
dc.subject | pathology | |
dc.subject | physiology | |
dc.subject | spermatogonium | |
dc.subject | testis | |
dc.subject | testis tumor | |
dc.subject | transgenic mouse | |
dc.subject | tumor suppressor gene | |
dc.subject | Amino Acid Substitution | |
dc.subject | Animals | |
dc.subject | Animals, Newborn | |
dc.subject | Apoptosis | |
dc.subject | Arginine | |
dc.subject | DNA Damage | |
dc.subject | Embryo, Mammalian | |
dc.subject | Genes, p53 | |
dc.subject | Histidine | |
dc.subject | Male | |
dc.subject | Mice | |
dc.subject | Mice, Transgenic | |
dc.subject | Mutant Proteins | |
dc.subject | Mutation Rate | |
dc.subject | Spermatogonia | |
dc.subject | Testicular Neoplasms | |
dc.subject | Testis | |
dc.type | Article | |
dc.contributor.department | MEDICINE | |
dc.description.doi | 10.1038/onc.2016.374 | |
dc.description.sourcetitle | Oncogene | |
dc.description.volume | 36 | |
dc.description.issue | 14 | |
dc.description.page | 2002-2013 | |
dc.published.state | Published | |
Appears in Collections: | Elements Staff Publications |
Show simple item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10_1038_onc_2016_374.pdf | 20.01 MB | Adobe PDF | OPEN | None | View/Download |
This item is licensed under a Creative Commons License